Core Insights - The article highlights the recent acquisition by Heart通医疗 of the remaining 49% stake in Shanghai Zhaoxin, making it a wholly-owned subsidiary, with a total acquisition cost of RMB 170 million [1][2]. Company Overview - Heart通医疗, established in 2009 and officially registered in 2015, focuses on innovative medical devices for structural heart diseases, with its headquarters in Shanghai and listed on the Hong Kong Stock Exchange in 2021 [2]. - The company emphasizes research and innovation, developing a comprehensive range of transcatheter and surgical solutions for structural heart diseases, including products for transcatheter aortic valve implantation (TAVI) [2]. Market Performance - Shanghai Zhaoxin specializes in left atrial appendage-related medical devices, with its core product, the AnchorMan left atrial appendage occlusion system, receiving NMPA approval for market entry in January 2024 [5][6]. - The TAVI series products of Heart通医疗 are already in over 650 hospitals across China, and the company has expanded its international presence to nearly a hundred hospitals in countries like Argentina, Colombia, and Switzerland [4]. Product Development - The AnchorMan left atrial appendage occlusion system has shown promising clinical results, achieving a 98.1% clinical success rate and a 100% left atrial appendage occlusion success rate in a one-year follow-up study [7].

报名：首届全球眼科大会 | 议程更新 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 合作伙伴征集：2025全球手术机器人大会 心未来 2025年3月30日， 心通医疗 发布截至2024年12月31日止年度业绩公告。 # 财报数据 # 关于心通 医疗 2024年公司实现收入 3.62亿 元，同比增长 7.5% ，收入增长主要得益于 二代主瓣产品及主动脉瓣膜球囊 在全球市场的持续商业化，特别是TAVI产品在海外市场的收入快速增长。 此外，子公司佐心医疗的左 心耳封堵器在中国正式商业化，为集团带来新的收入贡献。分地区来看，公司24年国内收入3.38亿元， 同比增长4.0%；海外地区实现收入0.24亿元，同比增长108.3%。经计算，公司H2实现收入1.38亿元，同 比下降13.4%。 公司24年实现毛利率 69.5% ，同比增加 1.1 pct ， 主要得益于公司采取的有效降本控费措施，以及业务 增长带来的规模效应。 公司24年归母净利润亏损 0.49亿 元，同比亏损收窄 89.5% ， 亏损大幅收窄主要得益于：收入增长、生 产成本下降及毛利率提升；公司通过统筹内外部资源、发挥集中效 ...